These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections. Shin YU; Hong EH; Lim HW; Kang MH; Seong M; Cho H BMC Ophthalmol; 2017 Oct; 17(1):182. PubMed ID: 28974211 [TBL] [Abstract][Full Text] [Related]
64. Efficacy of intravitreal bevacizumab (Avastin) for short-term treatment of diabetic macular edema. Nagasawa T; Naito T; Matsushita S; Sato H; Katome T; Shiota H J Med Invest; 2009 Aug; 56(3-4):111-5. PubMed ID: 19763022 [TBL] [Abstract][Full Text] [Related]
65. Spectral domain OCT documented resolution of recalcitrant macular edema after intravitreal bevacizumab in branch retinal vein occlusion. Chalam KV; Keshavamurthy R; Brar VS Eur J Ophthalmol; 2008; 18(5):831-3. PubMed ID: 18850569 [TBL] [Abstract][Full Text] [Related]
66. Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema. Solaiman KA; Diab MM; Dabour SA Retina; 2013 Sep; 33(8):1623-9. PubMed ID: 23538584 [TBL] [Abstract][Full Text] [Related]
67. Subfoveal Neurosensory Detachment Flattening and Observe (SNF-Ob): A Novel Approach in Diabetic Macular Edema Management: A Potential Cost-Effective Treatment Strategy to Be Explored. Sharma A; Parachuri N; Kumar N; Kuppermann BD; Bandello F; Loewenstein A; Regillo CD Ophthalmol Retina; 2019 Nov; 3(11):1009-1011. PubMed ID: 31451440 [No Abstract] [Full Text] [Related]
68. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Lazic R; Lukic M; Boras I; Draca N; Vlasic M; Gabric N; Tomic Z Retina; 2014 Apr; 34(4):719-24. PubMed ID: 23975006 [TBL] [Abstract][Full Text] [Related]
69. Successful treatment of pseudophakic cystoid macular edema with intravitreal bevacizumab. Barone A; Prascina F; Russo V; Iaculli C; Primavera V; Querques G; Stella A; Delle Noci N J Cataract Refract Surg; 2008 Jul; 34(7):1210-2. PubMed ID: 18571091 [TBL] [Abstract][Full Text] [Related]
70. Anti-VEGF therapeutic approaches for diabetic macular edema. Khurana RN; Do DV; Nguyen QD Int Ophthalmol Clin; 2009; 49(2):109-19. PubMed ID: 19349791 [No Abstract] [Full Text] [Related]
71. Comment of article by Matsumoto Y. Campa C; D'Angelo S; Incorvaia C Retina; 2008 May; 28(5):782; author reply 782-3. PubMed ID: 18463528 [No Abstract] [Full Text] [Related]
72. Ranibizumab for diabetic macular edema difficult to treat with focal/grid laser. Kotsolis AI; Tsianta E; Niskopoulou M; Masaoutis P; Baltatzis S; Ladas ID Graefes Arch Clin Exp Ophthalmol; 2010 Nov; 248(11):1553-7. PubMed ID: 20585799 [TBL] [Abstract][Full Text] [Related]
73. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study. Szaflik JP; Szaflik J Retina; 2010 Sep; 30(8):1328-9; author reply 1329. PubMed ID: 20827155 [No Abstract] [Full Text] [Related]